EUVIMEDScopri EUVIMED
Crossref

Quality of Life During Oral Peanut Immunotherapy in the OPIA Trial

Alice L. Flanagan, Isabelle M. L. Bosi, Elizabeth H. Barnes, Peter Hsu, Dianne E. Campbell

Clinical & Experimental Allergy · 2026-11-20

DOI: 10.1111/cea.70476 ↗

At a glance

Journal article in Clinical & Experimental Allergy, published online on 2026-11-20. Written by Alice L. Flanagan and 4 co-authors. 50 references. Funded by: DBV Technologies, National Health and Medical Research Council.

AbstractDati bibliograficiCiteRelated studies

Abstract (original language)

Background

Health‐related quality of life (HRQoL) findings have varied between peanut oral immunotherapy (OIT) trials. The objective of this study was to compare changes in the HRQoL between the OIT and standard (control) treatment groups during the OPIA peanut OIT double‐blind randomised controlled trial and at long‐term follow‐up.

Methods

OPIA was a single‐centre, 3‐arm, double‐blind placebo‐controlled trial of peanut OIT in children aged 10–16 years. Standardised questionnaires (FAQLQ, FAIM, FAQLQ‐Parent Burden, PSS) and bespoke surveys were administered at 0, 6, 12 and 13.5 months, with 3‐year follow‐up. Changes in scores at different time points were analysed descriptively and using 2‐tailed T tests. A GEE model investigated the interaction between change in HRQoL score, treatment (OIT vs. standard care) and time. 3 year follow‐up surveys were analysed using descriptive statistics and qualitative analysis.

Results

Sixty‐five subjects were randomised and 61 participants completed the study. There was no evidence of difference in HRQoL score changes between the OIT and standard treatment groups from baseline to 12 months or 13.5 months. Furthermore, achieving OPIA's primary efficacy endpoint (tolerance of ≥ 1000 mg of peanut protein (cumulative dose 1449 mg) at month 13.5 double blind placebo‐controlled food challenge was not associated with a more favourable change in FAQLQ from baseline to end of study. Changes in global FAQLQ‐Parent proxy (FAQLQ‐PF) scores from baseline to 12 months were less favourable for carers of children who had experienced treatment‐related serious adverse events compared to those without such events (mean change 0.10 vs. −0.97, 0.0063).

Conclusions

OIT did not confer a HRQoL benefit over standard care in this cohort, based upon the tools used to assess HRQoL. Treatment‐related serious adverse effects negatively impacted FAQLQ‐Parent proxy scores.

Funding

  • DBV Technologies
  • National Health and Medical Research Council

Cite

APA

Flanagan, A. L., Bosi, I. M. L., Barnes, E. H., Hsu, P., & Campbell, D. E. (2026). Quality of Life During Oral Peanut Immunotherapy in the OPIA Trial. Clinical & Experimental Allergy. https://doi.org/10.1111/cea.70476

Vancouver

Flanagan AL, Bosi IML, Barnes EH, Hsu P, Campbell DE. Quality of Life During Oral Peanut Immunotherapy in the OPIA Trial. Clinical & Experimental Allergy. 2026. doi:10.1111/cea.70476

BibTeX
@article{Flanagan2026,
  author = {Flanagan, Alice L. and Bosi, Isabelle M. L. and Barnes, Elizabeth H. and Hsu, Peter and Campbell, Dianne E.},
  title = {Quality of Life During Oral Peanut Immunotherapy in the OPIA Trial},
  journal = {Clinical & Experimental Allergy},
  year = {2026},
  doi = {10.1111/cea.70476}
}
Start for free →